Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bladder cancer: molecular determinants of personalized therapy.

Current drug targets - 1 Jan 2015

Lopez-Beltran Antonio, Santoni Matteo, Massari Francesco, Ciccarese Chiara, Tortora Giampaolo, Cheng Liang, Moch Holger, Scarpelli Marina, Reymundo Carlos, Montironi Rodolfo

Abstract excerpt

Several molecular and genetic studies have provided new perspectives on the histologic classification of bladder tumors. Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Share to Prognosis

Share to Urinary Bladder Neoplasms

Share to Urothelium

Source

Identifiers

PMID: 25654736
DOI: 10.2174/1389450116666150204115756

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bladder cancer: molecular determinants of personalized therapy.PMID 25654736Read ↗

[Recent advances in bladder urothelial carcinogenesis].Semantic proximity Read ↗

[Molecular diagnostics of bladder cancer-practical ramifications].Semantic proximity Read ↗

Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer: Progress and Challenges.Semantic proximity Read ↗

New discoveries in the molecular landscape of bladder cancerSemantic proximity Read ↗

Molecular pathogenesis of urothelial carcinoma: the clinical utility of emerging new biomarkers and future molecular classification of bladder cancer.Semantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.Semantic proximity Read ↗

Molecular pathogenesis and diagnostics of bladder cancer.Semantic proximity Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancerSemantic proximity Read ↗

Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.Semantic proximity Read ↗

Molecular Basis of Urinary Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.